// App-Quantinova.ai

P640 : PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN COMBINATION WITH VENETOCLAX±RITUXIMAB IN RELAPSED/REFRACTORY CLL: RESULTS FROM THE BRUIN PHASE 1B STUDY

Researchers

Presenter

  • Lindsey E. Roeker

Principal Investigators

  • Anthony R. Mato

  • Jennifer R. Brown

  • Catherine C. Coombs

  • Nirav N. Shah

  • William G. Wierda

  • Manish R. Patel

  • Katharine L. Lewis

  • Minna Balbas

  • Nora C. Ku

  • Binoj Nair

  • Chan Y. Cheah

Medical Centers

  • University of North Carolina at Chapel Hill,Chapel Hill,Estados Unidos

  • Loxo Oncology,Stamford,Verenigde Staten

  • University of North Carolina at Chapel Hill, Chapel Hill, NC, United States

  • Loxo Oncology,Stamford,Verenigde Staten

  • Medical College of Wisconsin, Milwaukee, Wisconsin , United States

  • Loxo Oncology at Lilly ,Stamford,Stati Uniti

  • Linear Clinical Research/Sir Charles Gairdner Hospital, Nedlands, Australia

  • Florida Cancer Specialists/Sarah Cannon Research Institute,Sarasota,Vereinigte Staaten

  • MD Anderson Cancer Center,Houston, TX,Estados Unidos

  • Loxo Oncology,Stamford,Verenigde Staten

  • MD Anderson Cancer Center,Houston, TX,Estados Unidos

  • Dana-Farber Ca

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • University of North Carolina, Chapel Hill, NC

  • Linear Clinical Research and Sir Charles Gairdner Hospital,Perth,Australie

  • Linear Clinical Research and Sir Charles Gairdner Hospital,Perth,Australie

  • Linear Clinical Research and Sir Charles Gairdner Hospital,Perth,Australie

  • Memorial Sloan Kettering Cancer Center,New York ,États-unis

  • MD Anderson Cancer Center ,Houston,Verenigde Staten

  • University of North Carolina at Chapel Hill,Chapel Hill,Estados Unidos

  • Medical College of WI

  • Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

  • Loxo Oncology,Stamford,Verenigde Staten

  • Linear Clinical Res

  • Medical College of Wisconsin ,Milwaukee,Vereinigte Staaten

  • Dana-Farber Cancer Institute, Harvard Medical School ,Boston,Verenigde Staten

  • MD Anderson Cancer Center ,Houston,Verenigde Staten

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • University of North Carolina at Chapel Hill,Chapel Hill,Estados Unidos

  • Linear Clinical Res

  • Florida Cancer Specialists/Sarah Cannon Research Institute ,Sarasota,Stati Uniti

  • Loxo Oncology,Stamford,Verenigde Staten

  • Memorial Sloan Kettering Cancer Center,New York,Vereinigte Staaten

  • Memorial Sloan Kettering, NY

  • Loxo Oncology at Li

  • Medical College of Wisconsin, Milwaukee,États-unis

  • Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

  • Medical College of Wisconsin, Milwaukee,États-unis

  • Memorial Sloan Kettering Cancer Center,New York,Vereinigte Staaten

  • Florida Cancer Specialists and Research Institute, Sarasota, FL

  • MD Anderson Cancer Center,Houston, TX,Estados Unidos

  • Medical College of Wisconsin, Milwaukee,États-unis

  • Medical College of Wisconsin ,Milwaukee,Vereinigte Staaten

  • University of Texas MD Anderson Cancer Center, Houston, Texas, United States

  • Linear Clinical Research and Sir Charles Gairdner Hospital,Perth,Australie

  • Loxo Oncology,Stamford,Verenigde Staten

  • Linear Clinical Research/Sir Charles Gairdner Hospital, Nedlands, Australia

  • Florida Cancer Specialists/Sarah Cannon Research Institute,Sarasota,Vereinigte Staaten

  • University of North Carolina at Chapel Hill, Chapel Hill, NC, United States

  • MD

  • Loxo Oncology at Lilly ,Stamford,Stati Uniti

  • Loxo Oncology at Lilly,Stam

  • Loxo Oncology at Lilly ,Stamford,Stati Uniti

  • Loxo Oncology at Lilly ,Stamford,Stati Uniti

  • Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

  • Memorial Sloan-Kettering Cancer Center, New York, NY, United States

  • Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

  • Florida Cancer Specialists/Sarah Cannon Research Institute,Sarasota,Vereinigte Staaten

Locations

  • United States

  • United Kingdom

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • B cell lymphomas

Biomarkers

  • Bruton tyrosine kinase

Drug/Treatment

  • Venetoclax

  • Rituximab

Outcome

  • N/A

Study Design

  • Multicenteric

Phase

  • I

Study Id's

  • NCT03740529

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved